HU0203316A3 - Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them - Google Patents

Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HU0203316A3
HU0203316A3 HU0203316A HU0203316A HU0203316A3 HU 0203316 A3 HU0203316 A3 HU 0203316A3 HU 0203316 A HU0203316 A HU 0203316A HU 0203316 A HU0203316 A HU 0203316A HU 0203316 A3 HU0203316 A3 HU 0203316A3
Authority
HU
Hungary
Prior art keywords
amino
pharmaceutical compositions
triazolopyridine derivatives
triazolopyridine
derivatives
Prior art date
Application number
HU0203316A
Other languages
Hungarian (hu)
Other versions
HU0203316A2 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99117578 priority Critical
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to PCT/EP2000/008372 priority patent/WO2001017999A2/en
Publication of HU0203316A2 publication Critical patent/HU0203316A2/en
Publication of HU0203316A3 publication Critical patent/HU0203316A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HU0203316A 1999-09-06 2000-08-28 Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them HU0203316A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99117578 1999-09-06
PCT/EP2000/008372 WO2001017999A2 (en) 1999-09-06 2000-08-28 Amino-triazolopyridine derivatives

Publications (2)

Publication Number Publication Date
HU0203316A2 HU0203316A2 (en) 2003-01-28
HU0203316A3 true HU0203316A3 (en) 2004-07-28

Family

ID=8238933

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203316A HU0203316A3 (en) 1999-09-06 2000-08-28 Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (22)

Country Link
US (1) US6355653B1 (en)
EP (1) EP1214322A2 (en)
JP (1) JP2003528811A (en)
KR (1) KR20020027625A (en)
CN (1) CN1379777A (en)
AR (1) AR037484A1 (en)
AU (1) AU7511000A (en)
BR (1) BR0013792A (en)
CA (1) CA2383998A1 (en)
CZ (1) CZ20021220A3 (en)
HR (1) HRP20020172A2 (en)
HU (1) HU0203316A3 (en)
IL (1) IL148167D0 (en)
MA (1) MA26816A1 (en)
MX (1) MXPA02001748A (en)
NO (1) NO20021077L (en)
PE (1) PE20010629A1 (en)
PL (1) PL354240A1 (en)
TR (1) TR200200579T2 (en)
WO (1) WO2001017999A2 (en)
YU (1) YU13502A (en)
ZA (1) ZA200201055B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506772B1 (en) 2000-12-15 2003-01-14 Hoffmann-La Roche Inc. Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
MXPA04003277A (en) * 2001-10-08 2004-07-23 Hoffmann La Roche 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide.
EP1453836B1 (en) 2001-11-30 2007-03-28 Schering Corporation BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
HU0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
EP2942082B1 (en) 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a receptor antogonists for use in the treatment of movement disorders
MXPA04012566A (en) * 2002-06-13 2005-04-19 Pfizer Non-peptide gnrh agents, pharmaceutical compositions and methods for their use.
US20080033006A1 (en) * 2004-01-26 2008-02-07 Altana Pharma Ag 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors
CA2591125A1 (en) 2004-12-21 2006-06-29 Schering Corporation Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
ES2273599B1 (en) 2005-10-14 2008-06-01 Universidad De Barcelona COMPOUNDS FOR THE TREATMENT OF HEADPHONE FIBRILATION.
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CN101516839A (en) * 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 Compounds which modulate the cb2 receptor
KR20090094336A (en) * 2006-11-27 2009-09-04 하. 룬트벡 아크티에 셀스카브 Heteroaryl amide derivatives
DE602007012133D1 (en) 2006-12-01 2011-03-03 Andrew Burritt TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
UA99610C2 (en) * 2007-04-10 2012-09-10 Х. Луннбэк А/С Heteroaryl amide analogues as p2x7 antagonists
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5492092B2 (en) * 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
JP2011520884A (en) * 2008-05-13 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sulfone compounds that modulate the CB2 receptor
SG178812A1 (en) * 2008-06-20 2012-03-29 Genentech Inc Triazolopyridine jak inhibitor compounds and methods
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US8178568B2 (en) * 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
TWI453207B (en) * 2008-09-08 2014-09-21 Signal Pharm Llc Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
CN102164916A (en) * 2008-09-25 2011-08-24 贝林格尔.英格海姆国际有限公司 Compounds which selectively modulate the CB2 receptor
MY153913A (en) * 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102459258B (en) 2009-06-05 2015-11-25 赛福伦公司 The preparation of 1,2,4-triazolo [1,5a] pyridine derivate and purposes
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (en) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Azetidine 2-carboxamide derivative that modulates CB2 receptor
AU2010271732B2 (en) * 2009-07-17 2016-08-25 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
US8383651B2 (en) * 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (en) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
JP5746228B2 (en) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tetrazole compound that selectively modulates CB2 receptor
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
WO2013041472A1 (en) * 2011-09-19 2013-03-28 F. Hoffmann-La Roche Ag Triazolopyridine compounds as pde10a inhibitors
EP2757883B1 (en) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3429997A1 (en) 2016-03-16 2019-01-23 Bayer CropScience Aktiengesellschaft N-(cyanobenzyl)-6-(cyclopropyl-carbonylamino)-4-(phenyl)-pyridine-2-carboxamide derivatives and related compounds as pesticides and plant protection agents
CN106543175B (en) * 2016-10-28 2018-06-01 上海大学 Triaryl [1,2,4] triazole [1,5-a] pyridine derivate and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
WO1999043678A1 (en) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for parkinson's disease

Also Published As

Publication number Publication date
WO2001017999A2 (en) 2001-03-15
EP1214322A2 (en) 2002-06-19
CA2383998A1 (en) 2001-03-15
NO20021077D0 (en) 2002-03-05
AR037484A1 (en) 2004-11-17
US6355653B1 (en) 2002-03-12
ZA200201055B (en) 2003-07-30
JP2003528811A (en) 2003-09-30
HU0203316A2 (en) 2003-01-28
CN1379777A (en) 2002-11-13
KR20020027625A (en) 2002-04-13
YU13502A (en) 2004-11-25
HRP20020172A2 (en) 2003-10-31
IL148167D0 (en) 2002-09-12
TR200200579T2 (en) 2002-12-23
CZ20021220A3 (en) 2002-10-16
AU7511000A (en) 2001-04-10
PL354240A1 (en) 2003-12-29
MA26816A1 (en) 2004-12-20
WO2001017999A3 (en) 2001-12-06
PE20010629A1 (en) 2001-05-30
NO20021077L (en) 2002-03-05
MXPA02001748A (en) 2002-08-06
BR0013792A (en) 2002-05-14

Similar Documents

Publication Publication Date Title
HU0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HU0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HU0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0203294A3 (en) Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0000748A2 (en) 4-phenyl-piridine derivatives, process for producing them and pharmaceutical compositions containing them
HU0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HU0105114A3 (en) Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation
HU0103082A3 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
HU0201753A3 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HU0103404A3 (en) Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
HU0203052A3 (en) Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HK1046902A1 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for their preparation
HU0203140A3 (en) Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HU0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HU0203385A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HU0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HU0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
SI1078928T1 (en) Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HU0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HU0105479A3 (en) Betha-alanine derivatives, process for producing them and pharmaceutical compositions containing them
HU0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them